Earnings ·
ImmuCell Corporation reported unaudited financial results for the quarter ended June 30, 2026
ICCCImmucell Corp
ImmuCell Corporation reported unaudited financial results for the quarter ended June 30, 2026. Revenue increased 11.5% to $7.2 million, while net income rose to $1.8 million, or $0.20 per diluted share, compared to $0.5 million in the prior year period. The earnings improvement was significantly aided by a one-time $2 million legal settlement payment from a former contract manufacturer. Gross margin declined to 34% due to lower manufacturing volumes and absorbed costs from a discontinued program. Cash on hand increased to $8.9 million, supported by the settlement and operating cash flows of $6.6 million for the first half of the year. The company is an animal health biologics firm that develops, manufactures, and markets products to improve calf health and productivity.